Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16292
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWee, Eugene JH-
dc.contributor.authorWang, Yuling-
dc.contributor.authorTsao, Simon Chang-Hao-
dc.contributor.authorTrau, Matt-
dc.date2016-06-17-
dc.date.accessioned2016-09-26T23:55:50Z-
dc.date.available2016-09-26T23:55:50Z-
dc.date.issued2016-06-17-
dc.identifier.citationTheranostics 2016; 6(10): 1506-1513en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16292-
dc.description.abstractSensitive and accurate identification of specific DNA mutations can influence clinical decisions. However accurate diagnosis from limiting samples such as circulating tumour DNA (ctDNA) is challenging. Current approaches based on fluorescence such as quantitative PCR (qPCR) and more recently, droplet digital PCR (ddPCR) have limitations in multiplex detection, sensitivity and the need for expensive specialized equipment. Herein we describe an assay capitalizing on the multiplexing and sensitivity benefits of surface-enhanced Raman spectroscopy (SERS) with the simplicity of standard PCR to address the limitations of current approaches. This proof-of-concept method could reproducibly detect as few as 0.1% (10 copies, CV < 9%) of target sequences thus demonstrating the high sensitivity of the method. The method was then applied to specifically detect three important melanoma mutations in multiplex. Finally, the PCR/SERS assay was used to genotype cell lines and ctDNA from serum samples where results subsequently validated with ddPCR. With ddPCR-like sensitivity and accuracy yet at the convenience of standard PCR, we believe this multiplex PCR/SERS method could find wide applications in both diagnostics and research.en_US
dc.subjectSERSen_US
dc.subjectMultiplex PCRen_US
dc.subjectMelanomaen_US
dc.subjectBRAFen_US
dc.subjectcKITen_US
dc.subjectNRASen_US
dc.subjectctDNAen_US
dc.titleSimple, sensitive and accurate multiplex detection of clinically important melanoma DNA mutations in circulating tumour DNA with SERS nanotagsen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleTheranosticsen_US
dc.identifier.affiliationCenter for Personalized Nanomedicine, Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland, Australiaen_US
dc.identifier.affiliationSchool of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27446486en_US
dc.identifier.doi10.7150/thno.15871en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.